Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Lucentis in neovascular age-related macular degeneration
2007-000743-95Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Novartis. Primary endpoint: Incidence and severity of treatment-emergent ocular and non-ocular adverse events. Started Jun 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2007-000743-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000743-95.